logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9552457 B1

PDFFull Text
Date of Patent:
Jan. 24, 2017

Filed:

Feb. 27, 2013

Reprogramming effector protein interactions to correct epigenetic defects in cancer

Applicant:

British Columbia Cancer Agency Branch, Vancouver, CA;

Inventors:

Steven J. M. Jones, Vancouver, CA;

Oleksandr Yakovenko, Vancouver, CA;

Silvia Thoene, Vancouver, CA;

Pierre Yulmin Cheung, Vancouver, CA;

Jianghong An, Vancouver, CA;

Assignee:

BRITISH COLUMBIA CANCER AGENCY BRANCH, Vancouver, CA;

Attorneys:

Laura M. Lloyd

Leech Tishman Fuscaldo & Lampl

Primary Examiner:

Michael Borin

Int. Cl.
CPC ...
G06F 19/16 (2011.01); A61K 31/137 (2006.01); A61K 31/47 (2006.01); A61K 31/46 (2006.01); A61K 31/10 (2006.01); A61K 31/135 (2006.01); A61K 31/167 (2006.01); A61K 31/245 (2006.01); A61K 31/36 (2006.01); A61K 31/407 (2006.01); A61K 31/5375 (2006.01); C40B 30/02 (2006.01); G06F 19/00 (2011.01); A61K 31/343 (2006.01); A61K 31/4709 (2006.01);
U.S. Cl.
CPC ...
G06F 19/16 (2013.01); A61K 31/10 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/245 (2013.01); A61K 31/343 (2013.01); A61K 31/36 (2013.01); A61K 31/407 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/5375 (2013.01); C40B 30/02 (2013.01); G06F 19/706 (2013.01);
Abstract

Methods of 'reprogramming' epigenetic mark readers or erasers to recognize epigenetic marks other than their cognate (or natural) marks are provided. Reprogramming the reader or eraser can offset the effects of aberrant writer activity (for example, loss of function or overactivity) that can contribute to certain diseases states, such as cancer. The use of the reprogramming compounds identified by these methods in the treatment of such disease states is also provided. Exemplary mark readers that can be targeted by these methods include BPTF and CBX2.

Find Patent Forward Citations

Loading…